Anlotinib plus chemotherapy shows promise in treating advanced soft tissue sarcoma

The combination of anlotinib with chemotherapy shows promising efficacy and tolerability for treating advanced soft tissue sarcoma (STS), with encouraging response rates and manageable side effects, supporting further clinical research, according to a study.

The study included 14 patients with various STS subtypes, including liposarcoma, undifferentiated polymorphic sarcoma, and synovial sarcoma. Most patients (n = 13) received the combination as a first-line therapy, while 1 patient received it as a second-line option. Treatment regimens primarily involved anthracyclines, ifosfamide, and paclitaxel. Outcomes were assessed after every 2 treatment cycles.

Of the 14 participants, 5 achieved partial responses PR, while 7 experienced stable disease. Two cases showed disease progression. The overall response rate was 35.7%, and the disease control rate reached 83.3% among non-surgical patients. The median progression-free survival was 8.25 months.

Common side effects included bone marrow suppression, nausea, vomiting, and hypertension, while 3 patients developed severe febrile neutropenia. No treatment-related deaths were reported.

Reference
Ni Y, Dong Y, Jiang A, et al. The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma. Discov Oncol. 2024;15(1):598. doi: 10.1007/s12672-024-01492-1. PMID: 39467879.